RBC on Legend Biotech Corp. (LEGN): 'We Think Shares Remain Undervalued'

April 20, 2026 10:51 AM

RBC Capital analyst Leonid Timashev reiterated an Outperform rating and $62.00 price target on Legend Biotech Corp. (NASDAQ: LEGN).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found